bioRxiv · 10.1101/265959
A new paradigm for personalized cancer screening
Abstract
A series of distinct histologic lesions precedes the onset of malignancy in many common cancers, yet early detection remains a major challenge. Many patients still experience late (stage IV) diagnoses and thus poor prognosis and limited options for therapeutic intervention. For cancers with known biomarkers of premalignant progression, optimized patient-specific screening protocols would minimize the risk of undetected progression to advanced stage disease. Here, we propose simple, cost-effective mathematical and statistical approaches to forecasting disease progression that could guide the personalization of optimal screening times for high-risk patients.
Explore related subjects
Keep this discovery
Walker, R., Enderling, H.. 2018-02-15. A new paradigm for personalized cancer screening. https://doi.org/10.1101/265959
Cite the original work for its findings. Save a collection to share your selection of sources.